Eli Lilly has formed a partnership with Hong Kong's Metis TechBio worth up to $1.1 billion, gaining access to an AI drug delivery platform designed to improve therapeutic performance of drugs carried by lipid nanoparticles. The collaboration will center on Metis' ionizable lipid discovery and optimization platform called AiLNP, which the company touts as the “world's first and only de novo lipid generation algorithm,” relying on a large lipid library, end-to-end screening and a lipid language mo

Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo. The all-cash deal will see Darmstadt-based Merck pay $20 per American depositary share, with each ADS representing three ordinary shares of Silence. The biggest prize for Merck is divesiran, a short interfering RNA (siRNA) drug candidate designed to treat a rare blood cancer called polycythemia vera (PV). The cancer is

Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to take the reins. Shionogi is handing over $2 billion for the Austin, Texas-based commercial biotech, in a deal that—in addition to Aqneursa—will grant access to IntraBio’s rare disease expertise and pipeline. The acquisition builds on Shionogi’s plans to diversify beyond its anti-infectious disease drug base and to beef up its budding rare disease unit, which was founded

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease Oct. 19, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FU

The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors. Gilead Sciences has helped bolster the appeal of Vir Biotechnology’s T cell engager technology with a new licensing deal that includes $135 million in upfront and near-term payments—including an equity stake—and could tack on an additional $1.74 billion in milestones. The upfront payment includ

Alaunos Therapeutics has bought Velaris Therapeutics, adding four biologics candidates discovered by Paragon Labs targeting pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The transaction coincides with Paragon building out its own leadership bench with former executives from Apogee Therapeutics, another company — recently acquired by AbbVie for $10.9 billion — that had been built around Paragon-discovered assets. The Velaris buyout was accompanied by an oversubscribe

Oct. 13, 2026 -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform. ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a genetically validated target for obesity and metabolic diseases. Inhibition of ALK7 by directly targeting adipocytes has

Oct. 12, 2026 -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting

Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development. Oct. 12, 2026 -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a strategic collaboration with Discovery Life Sciences (Discovery), a global leader in biospecimens and specialty la

Viatris will acquire the rights to Exparel and Zilretta if this acquisition goes ahead. Credit: Dragana Gordic / Shutterstock.com. California-based healthcare company Viatris has inked a billion-dollar deal to acquire Pacira BioSciences and its non-opioid pain management therapies – allowing the company to enter a market attracting growing attention amid the ongoing effects from the opioid crisis in the US. Through this deal, Viatris will pay $36.50 in cash per share for Pacira’s remaining stock